• Company Information
  • Business Outline
  • Pipeline
  • IR Information
  • Contact

News Overview

  • All
  • News Release
  • IR News
  • Publications
  • Others
Sep. 25, 2014
Publications
The paper relating to OBP-401 (TelomeScan®) was published on Cancer
Feb. 2014
Publications
The paper relating to OBP-401 (TelomeScan®) was published on Cancer Research
Jan. 22, 2014
News Release
Oncolys BioPharma Initiates Phase I/II Clinical Study of OBP-301(Telomelysin) in Liver Cancer
Dec. 06, 2013
News Release
Oncolys BioPharma was listed on the Tokyo Stock Exchange Mothers
Oct. 31, 2013
News Release
Oncolys BioPharma Received Approval to List on Tokyo Stock Exchange Mothers
Oct. 31, 2013
Others
Homepage Renewal
Oct. 20, 2011
News Release
Global Licensing Agreement for Investigational HIV Compound (OBP-601) Wins 2011 Deals of Distinction™ Award
Dec. 20, 2010
News Release
Bristol-Myers Squibb and Oncolys BioPharma Enter Global Licensing Agreement For Investigational HIV Compound
Oct. 13, 2009
News Release
ONCOLYS BIOPHARMA SIGN STRATEGIC ALLIANCE AND LICENSE AGREEMENT WITH ASTELLAS PHARMA TO DEVELOP AND COMMERCIALIZE YM753 HDAC INHIBITOR DRUG
Feb. 10, 2009
News Release
Oncolys BioPharma Inc. Presented A Result of Phase Ia Clinical Study for OBP-601, A Novel Anti-HIV Drug, at 16th CROI Held in Montreal, Canada.
Feb. 04, 2009
News Release
Oncolys BioPharma Inc. commenced a repeated dose phase Ib clinical study for OBP-601, a novel anti-HIV drug, in HIV infected patients.
Jan. 21, 2009
News Release
ONCOLYS BIOPHARMA AND SYSMEX CORPORATON SIGN COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR IN-VITRO CANCER CIRCULATING TUMOR CELL DIAGNOSTIC AGENT
May. 29, 2008
News Release
ONCOLYS BIOPHARMA DISCLOSED THE INTERIM CLINICAL RESULT OF A PHASE I CLINICAL TRIAL OF TELOMELYSIN™ (OBP-301) AT ASCO 2008 (AMERICAN SOCIETY OF CLINICAL ONCOLOGY), IN CHICAGO
Apr. 15, 2008
News Release
OBP-601 successfully passed the US FDA IND review process and is ready to initiate Ph-I clinical trial in the United States.
Mar. 24, 2008
News Release
Oncolys BioPharma, Inc. Raises $8.2Million (JPY 815,980,000) In Equity Private Placements
Mar. 18, 2008
News Release
Oncolys BioPharma Inc. submitted an IND for OBP-601,a novel anti-HIV drug, to the FDA to gain permission to initiate Ph-Iclinical trial in human.
Mar. 13, 2008
News Release
ONCOLYS BIOPHARMA AND TACERE THERAPEUTICS SIGN STRATEGIC ALLIANCE AND LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE RNAi HEPATITIS C DRUG
Mar. 06, 2008
News Release
Oncolys BioPharma and Medigen Biotechnology Enters Strategic Alliance and License Agreement to Develop and Commercialize Telomelysin:® (OBP-301) for a Potential New Treatment for Solid Tumors
Nov. 05, 2007
News Release
Oncolys BioPharma Opens New Research Center in Kobe
Nov. 2007
Publications
The paper relating to OBP-601 was published on Antimicrobial Agents And Chemotherapy
May. 2007
Publications
The paper relating to OBP-601 was published on Antimicrobial Agents And Chemotherapy
Jun. 21, 2007
News Release
ONCOLYS BIOPHARMA AND TACERE THERAPEUTICS FORM STRATEGIC ALLIANCE TO DEVELOP RNAi HEPATITIS C DRUG
Nov. 02, 2006
News Release
Oncolys BioPharma, Inc. Raises $23.8 Million (JPY 2.6 Billion) In Equity Private Placement
Oct. 31, 2006
News Release
Oncolys BioPharma Announces That The First Patient Is in The Phase I Clinical Study of Telomelysin® for Solid Tumors in US
Oct. 11, 2006
News Release
Oncolys BioPharma Opened Own Research Center
Oct. 2006
Publications
The paper relating to OBP-401 (TelomeScan®) was published on Nature Medicine
Aug. 25, 2006
News Release
Japan's First Anti-cancer Adenovirus Is Now GO for Clinical Studies in US
Jul. 2006
Publications
The paper relating to OBP-401 (TelomeScan®) was published on International Journal of Cancer
Jun. 27, 2006
News Release
Yale Licenses Potential Anti-HIV Agent to Oncolys BioPharma of Japan Link・・・http://www.yale.edu/opa/newsr/06-06-27-01.all.html
Feb. 2006
Publications
The paper relating to OBP-301 (Telomelysin®) was published on Experimental Cell Research
Aug. 2005
Publications
The paper relating to OBP-601 was published on Antimicrobial Agents And Chemotherapy
Sep. 2004
Publications
The paper relating to OBP-401 (TelomeScan®) was published on Cancer Research
May. 2004
Publications
The paper relating to OBP-601 was published on Antimicrobial Agents And Chemotherapy
Jan. 2004
Publications
The paper relating to OBP-301 (Telomelysin®) was published on Clinical Cancer Research
Jan. 22, 2014
News Release
Oncolys BioPharma Initiates Phase I/II Clinical Study of OBP-301(Telomelysin) in Liver Cancer
Dec. 06, 2013
News Release
Oncolys BioPharma was listed on the Tokyo Stock Exchange Mothers
Oct. 31, 2013
News Release
Oncolys BioPharma Received Approval to List on Tokyo Stock Exchange Mothers
Oct. 20, 2011
News Release
Global Licensing Agreement for Investigational HIV Compound (OBP-601) Wins 2011 Deals of Distinction™ Award
Dec. 20, 2010
News Release
Bristol-Myers Squibb and Oncolys BioPharma Enter Global Licensing Agreement For Investigational HIV Compound
Oct. 13, 2009
News Release
ONCOLYS BIOPHARMA SIGN STRATEGIC ALLIANCE AND LICENSE AGREEMENT WITH ASTELLAS PHARMA TO DEVELOP AND COMMERCIALIZE YM753 HDAC INHIBITOR DRUG
Feb. 10, 2009
News Release
Oncolys BioPharma Inc. Presented A Result of Phase Ia Clinical Study for OBP-601, A Novel Anti-HIV Drug, at 16th CROI Held in Montreal, Canada.
Feb. 04, 2009
News Release
Oncolys BioPharma Inc. commenced a repeated dose phase Ib clinical study for OBP-601, a novel anti-HIV drug, in HIV infected patients.
Jan. 21, 2009
News Release
ONCOLYS BIOPHARMA AND SYSMEX CORPORATON SIGN COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR IN-VITRO CANCER CIRCULATING TUMOR CELL DIAGNOSTIC AGENT
May. 29, 2008
News Release
ONCOLYS BIOPHARMA DISCLOSED THE INTERIM CLINICAL RESULT OF A PHASE I CLINICAL TRIAL OF TELOMELYSIN™ (OBP-301) AT ASCO 2008 (AMERICAN SOCIETY OF CLINICAL ONCOLOGY), IN CHICAGO
Apr. 15, 2008
News Release
OBP-601 successfully passed the US FDA IND review process and is ready to initiate Ph-I clinical trial in the United States.
Mar. 24, 2008
News Release
Oncolys BioPharma, Inc. Raises $8.2Million (JPY 815,980,000) In Equity Private Placements
Mar. 18, 2008
News Release
Oncolys BioPharma Inc. submitted an IND for OBP-601,a novel anti-HIV drug, to the FDA to gain permission to initiate Ph-Iclinical trial in human.
Mar. 13, 2008
News Release
ONCOLYS BIOPHARMA AND TACERE THERAPEUTICS SIGN STRATEGIC ALLIANCE AND LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE RNAi HEPATITIS C DRUG
Mar. 06, 2008
News Release
Oncolys BioPharma and Medigen Biotechnology Enters Strategic Alliance and License Agreement to Develop and Commercialize Telomelysin:® (OBP-301) for a Potential New Treatment for Solid Tumors
Nov. 05, 2007
News Release
Oncolys BioPharma Opens New Research Center in Kobe
Jun. 21, 2007
News Release
ONCOLYS BIOPHARMA AND TACERE THERAPEUTICS FORM STRATEGIC ALLIANCE TO DEVELOP RNAi HEPATITIS C DRUG
Nov. 02, 2006
News Release
Oncolys BioPharma, Inc. Raises $23.8 Million (JPY 2.6 Billion) In Equity Private Placement
Oct. 31, 2006
News Release
Oncolys BioPharma Announces That The First Patient Is in The Phase I Clinical Study of Telomelysin® for Solid Tumors in US
Oct. 11, 2006
News Release
Oncolys BioPharma Opened Own Research Center
Aug. 25, 2006
News Release
Japan's First Anti-cancer Adenovirus Is Now GO for Clinical Studies in US
Jun. 27, 2006
News Release
Yale Licenses Potential Anti-HIV Agent to Oncolys BioPharma of Japan Link・・・http://www.yale.edu/opa/newsr/06-06-27-01.all.html
Oct. 31, 2013
others
Homepage Renewal
pagetop